Publications by authors named "Hye-In Sim"
Cancer immunotherapy aims to initiate or amplify immune responses that eliminate cancer cells and create immune memory to prevent relapse. Immune checkpoint inhibitors (ICIs), which target coinhibitory receptors on immune effector cells, such as CTLA-4 and PD-(L)1, have made significant strides in cancer treatment. However, they still face challenges in achieving widespread and durable responses.
View Article and Find Full Text PDFBackground: Immunotherapy has significantly advanced cancer treatments, but many patients do not respond to it, partly due to immunosuppressive mechanisms used by tumor cells. These cells employ immunosuppressive ligands to evade detection and elimination by the immune system. Therefore, the discovery and characterization of novel immunosuppressive ligands that facilitate immune evasion are crucial for developing more potent anti-cancer therapies.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors are effective for some colon cancer patients with specific genetic features, but there's a need for better biomarkers to identify more patients who could benefit from this treatment.
- The study found that higher levels of PBK/TOPK, a protein involved in cell regulation, were linked to improved outcomes and greater immune cell presence in colon tumors.
- Additionally, high PBK/TOPK expression correlated with more mutations in DNA repair genes and cytotoxic T-cell activity, suggesting it could be a useful biomarker for predicting responses to immunotherapy in colon cancer patients.